Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer-Reference-Cited by-同舟云学术

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

Published:2010-12 Issue:3 Volume:119 Page:484-490
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Han Ernest S.,Burger Robert A.,Darcy Kathleen M.,Sill Michael W.,Randall Leslie M.,Chase Dana,Parmakhtiar Basmina,Monk Bradley J.,Greer Benjamin E.,Connelly Patrick,DeGeest Koen,Fruehauf John P.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference40 articles.

1. Epithelial ovarian cancer;DiSaia,2007

2. Vascular endothelial growth factor signaling pathways: therapeutic perspective;Kowanetz;Clin Cancer Res,2006

3. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study;Burger;J Clin Oncol,2007

4. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer;Cannistra;J Clin Oncol,2007

5. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret hospital phase II consortia;Garcia;J Clin Oncol,2008

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian Cancer;Laboratory Investigation;2023-11

2. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-04-18

3. Angiogenesis in diabetic mouse model with critical limb ischemia; cell and gene therapy;Microvascular Research;2022-05

4. Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy;Journal of Oncology;2022-04-12

5. AIM2 Inflammasome in Tumor Cells as a Biomarker for Predicting the Treatment Response to Antiangiogenic Therapy in Epithelial Ovarian Cancer Patients;Journal of Clinical Medicine;2021-09-30